Pulnovo Medical secures almost 100 million US dollars in Series C

Pulmonary hypertension therapy: Medtech Pulnovo Medical receives USD 100 million to further develop its minimally invasive treatment for pulmonary hypertension

Shanghai, March 3, 2025 - Medical device company Pulnovo Medical has announced the successful completion of a Series C financing round of nearly USD 100 million. The round was led by Qiming Venture Partners and Lilly Asia Ventures, with additional participation from OrbiMed and Gaorong Capital. The investment will be used for the company's global expansion, clinical trials and strategic initiatives.

Global recognition for innovative PADN technology

Pulnovo Medical is a leading company in the field of innovative therapies for pulmonary hypertension (PH) and heart failure (HF). The company's core product, Pulmonary Artery Denervation (PADN) technology, is a minimally invasive treatment for pulmonary hypertension. The method uses radiofrequency ablation to affect the pulmonary vascular nerve and thus lower the pressure in the pulmonary artery.

The FDA has classified PADN as a Breakthrough Device for various groups of PH, and in 2023 the procedure received a Humanitarian Use Exemption for Group I PH. The technology is already commercially available in China, Hong Kong and Macau, while global multi-center studies are ongoing in Portugal, Serbia, Georgia and Southeast Asia.

Funding strengthens international studies and market entry

With the newly raised funds, Pulnovo Medical plans to conduct two FDA trials for Group I and Group II PH this year. The company is also driving international expansion, with offices in the US, Singapore, Hong Kong and several cities in China, including Beijing and Shanghai.

Investors focus on global growth

The financing round was twice oversubscribed, underlining investors' confidence in Pulnovo Medical's innovative strength.

Pulnovo Medical is setting new standards in the interventional treatment of pulmonary hypertension and heart failure. The successful commercialization in China and the international studies demonstrate the clinical relevance of this technology. We are convinced that Pulnovo Medical will play a decisive role in the future of medical technology.

William Hu, Managing Partner of Qiming Venture Partners

The Series C financing positions Pulnovo Medical as a global innovator in medical technology. The advancement of PADN technology could bring new hope to millions of patients with pulmonary hypertension.